The President and CEO of Carl Zeiss Meditec AG, Dr. Markus Weber, has informed the Supervisory Board that he will leave the company of his own accord. The Supervisory Board acknowledges and deeply regrets Dr. Weber’s decision. Dr. Weber and the Supervisory Board reached a mutual agreement on the best of terms that his mandate as President and CEO will end on 31 May 2025.
Dr. Weber’s Departure and Legacy
The Supervisory Board has appointed Maximilian Foerst as the new President and CEO of Carl Zeiss Meditec AG effective 1 June 2025. As Head of ZEISS Greater China since 2009, he has been responsible for all business activities in what is now the ZEISS Group’s strongest market globally in terms of revenue, generating around two billion euros annually. In addition to the sales and services companies of all four ZEISS segments, he currently oversees seven production sites, three innovation centers, regional support functions and over 7,000 employees at more than 30 locations. Prior to this, he headed the ZEISS Group’s sales and service companies in Korea and France. The ZEISS Medical Technology segment plays a major role in all these markets. At Medical Technology, Maximilian Foerst previously served as Director of Sales and Marketing as well as Head of Product Management for Lasers at the Ophthalmology strategic business unit.
“Under Markus Weber’s leadership, Carl Zeiss Meditec AG has laid a very important strategic foundation and, as a technology leader in ophthalmology and microsurgery, is very well positioned for the future. With the acquisition of the company Dutch
Ophthalmic Research Center (D.O.R.C.), he successfully made a key addition to the company’s service portfolio,” says Andreas Pecher, Chairman of the Supervisory Board of Carl Zeiss Meditec AG and President and CEO of Carl Zeiss AG.
“The Supervisory Board of Carl Zeiss Meditec AG would like to thank Markus Weber for his exceptional dedication and extremely successful time as President and CEO. We very much regret his decision and wish him all the best in his future endeavors.”
“I would like to thank the Supervisory Board, all the customers, partners and all the employees for the excellent cooperation and for putting their trust in me,” says Dr. Weber. “After 22 years at ZEISS and being in my early 50s, now is the right time to once again take on an entirely new challenge. I wish my successor, Maximilian Foerst, all the best and continued success.”
Maximilian Foerst’s Appointment and Vision
Andreas Pecher is pleased to be able to appoint a highly competent successor from within the ZEISS Group. “With experience in international business and outstanding qualifications, Maximilian Foerst has successfully built up and expanded the ZEISS Group’s business in what for us is currently the strongest market globally in terms of revenue,” says Andreas Pecher. “In light of his experience at the ZEISS Medical Technology segment and its close alignment with customers in challenging international markets, he will successfully develop this important part of the ZEISS Group.”
Speaking about his appointment as President and CEO of Carl Zeiss Meditec AG, Maximilian Foerst said: “I am very much looking forward to this new position at Carl Zeiss Meditec AG. In challenging times, Carl Zeiss Meditec AG is very well positioned and aligned. The long-term potential of innovative medical technology is based on megatrends such as demographic change, the increasing importance of health and digitalization. Now, we have to leverage this with a keen eye to the diverse requirements of our global markets.”
Thus, starting 1 June 2025, the Management Board of Carl Zeiss Meditec AG will consist of Maximilian Foerst (President and CEO) and Justus Wehmer (Chief Financial Officer).
